EventsThe First International Conference on “Green” Polymer Materials 2020
Published
This submission belongs to the session S4. Biopolymers: Design, Fabrication, Characterization and Applications of the event The First International Conference on “Green” Polymer Materials 2020
Published date
04 Nov, 2020
Citation
Georgia Michailidou, Nina-Maria Ainali, Eleftheria Xanthopoulou, Dimitrios Bikiaris, Encapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Microparticles of Chitosan Derivative for COPD Treatment, in Proceedings of The First International Conference on “Green” Polymer Materials 2020, 5 November–25 November 2020, MDPI: Basel, Switzerland, doi: 10.3390/CGPM2020-07209
Share
Email
Facebook
Twitter
LinkedIn

Encapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Microparticles of Chitosan Derivative for COPD Treatment

image
image
1. Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Macedonia, Greece
2. Department of Chemistry, Aristotle University of Thessaloniki
Abstract

Chronic obstructive pulmonary disease (COPD) is associated with an enhanced chronic inflammation of the airways caused by tobacco smoking, air pollution or genetic factors. Fluticasone propionate, a corticosteroid with high topi­cal activity and salmeterol xinafoate, a long-acting selective β2-adrenoceptor agonist, are extensively used in COPD treatment. The main drawbacks of these pharmaceutical compounds are their high degree of crystallinity along with their hydrophobic nature. These problems, can be overcome through the inclusion of these compounds in polymeric microparticles aiming to their amorphization.

In the present study, chitosan was modified through a graft copolymerization with 2-hydroxyethyl acrylate. Microparticles of chitosan derivative were synthesized via ionic gelation technique and fluticasone propionate and salmeterol xinafoate were simultaneously enclosed in their interior in 10, 20 and 30% ratios. FTIR, X-ray diffraction, SEM and DLS measurements were conducted in order to characterize the microparticles while in vitro release studies were performed intending the assessment of the samples’ release behavior.

The successful formation of the microparticles was confirmed by FTIR while the absence of drugs’ crystallinity indicated their amorphization in the interior of the microparticles. SEM images depicted the spherical shaped particles while their actual size, which in any ratio was in micro scale, was measured through DLS. Finally, the enhancement of the in vitro release behavior of both active compounds was accomplished.

In conclusion, our results support the successful formulation of modified chitosan microparticles, the inclusion of both drugs in an amorphous state and the amelioration of their in vitro release behavior.

Acknowledgements:

Τhe author wishes to acknowledge co-funding of this research by European Union-European Regional Development Fund and Greek Ministry of Education, Research and Religions/EYDE-ETAK through program EPANEK 2014-2020/Action “EREVNO-DIMIOURGO-KAINOTOMO” (project Τ1ΕΔΚ-02667).

Keywords
Chitosan
nanoparticles
drugs
COPD
Manuscript
Oral Presentation
Poster
sciforum-037287 POSTER.pdf
Fluorescent EDOT-Functionalized Poly-E-Caprolactone: Synthesis, Photophysical and Self-Assembling Properties in Organic Solvents and Its Serendipitously Noticed Behaviour in Protonated Media
Biodegradable Plasticizing Composition for Plastics with a Limited Service Life